Breaking News, Collaborations & Alliances

PRISM BioLab, Lilly Enter PPI Discovery Collaboration

Aims to discover oral inhibitors of protein-protein interaction targets leveraging PRISM BioLab's PepMetics technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PRISM BioLab, Co. Ltd., a discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, has entered into a license and collaboration agreement with Eli Lilly and Co.   PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target selected by Lilly utilizing PRISM’s PepMetics technology. Lilly has the option to add up to two more targets and is responsible for clinical development and commercializ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters